DDI-DrugBank.d693.s0 >> Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. >> 22-31,37-43,119-131
DDI-DrugBank.d693.s1 >> When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. >> 20-32,58-69
DDI-DrugBank.d693.s2 >> Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. >> 15-27,67-78
DDI-DrugBank.d693.s3 >> The overall toxicity profile of the combination revealed an increased incidence of gastrointestinal adverse events, especially nausea, when compared to the incidence associated with either drug administered alone.
DDI-DrugBank.d693.s4 >> Drug/Laboratory Test Interactions: The presence of sulfasalazine or its metabolites in body fluids has not been reported to interfere with laboratory test procedures. >> 51-63
DDI-DrugBank.d693.s5 >> REFERENCES 7.Farr M, et al.
DDI-DrugBank.d693.s6 >> Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. >> 35-48
DDI-DrugBank.d693.s7 >> British Jnl Rheum 1991;30:413-417.
